title: Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study.
abstract: SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare disease. Presently, there is no treatment guideline for this illness. Several studies suggested entercept, a novel biological agent against tumor necrosis factor-alpha, is effective in treating SAPHO syndrome. We report a case in which the clinical conditions of a middle-aged female patient diagnosed with SAPHO syndrome, with noted spinal disorder, improved significantly after receiving entercept treatment. The patient remained stable after 3-month follow-up.
authors: Department of Cardiology, Aerospace Central Hospital, Beijing, China. zhanglili.cip@126.com
authors: L L
authors: LL
authors: Zhang
authors: J X
authors: JX
authors: Zhao
authors: X Y
authors: XY
authors: Liu
mesh_terms: D020083:Acquired Hyperostosis Syndrome / Q000000981:diagnostic imaging / Q000188:drug therapy*; D019386:Alendronate / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008875:Middle Aged; D059408:Pain Management / Q000379:methods; D011859:Radiography; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013122:Spinal Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D050071:Bone Density Conservation Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D012460:Sulfasalazine; D000068800:Etanercept; D019386:Alendronate